|
 |
Florian Schönharting
Florian Schönharting is co-founder and partner of Nordic Biotech. Mr. Schönharting is a pioneer in Biotechnology Investments and has more than 17 years of investment experience in the biotechnology and healthcare industry.
Prior to co-founding Nordic Biotech Advisors, Mr. Schönharting was directly responsible for 20+ investments ranging from seed to late stage at a Copenhagen based financial institution (BankInvest), resulting in 10+ IPOs or trade sales, including Biomarin Inc., Bavarian Nordic Research Institute, Pharmexa, Pyrosequencing, Glyko Biomedical and Profound Pharma A/S (Maxygen Inc.). Mr. Schönharting was also the initiator, architect and founder of Genmab A/S. In addition he was responsible for seedfunding Zealand Pharma A/S and 7TM Pharma A/S. Mr. Schönharting is a former board member of Acadia Pharmaceuticals Inc., Life Cycle Pharma A/S, Curalogic A/S and a current boardmember of Osteologix Inc., Forward Pharma A/S, Gastrotech Pharma A/S, Spree Pharma A/S and Entrop Pharma A/S.
Mr. Schönharting received a master's degree in business economics (finance) from the Copenhagen Business School, and was given the McKinsey & Co award for best-of-year student.
Florian Schönharting is currently member of the Board of Directors of the Danish Venture Capital Association (DVCA) and the Danish Corporate Governance Association (DCGA).
|
| |
|
| |
|
 |
Christian Hansen
Christian Hansen is co-founder and partner of Nordic Biotech. Dr. Hansen has a background as a biotech entrepreneur, biotech intellectual property rights expert and business development executive, combined with a scientific career. He has been actively involved in biotech investment since the late 1990’s.
From 2000 to 2001 Dr. Hansen was President of Maxygen's Protein Pharma Division, and Managing Director of its Danish subsidiary Maxygen ApS, employing about 75 people. From 1999 to 2000, Dr. Hansen was CEO and founder of ProFound Pharma A/S, a Danish start-up company focused on developing 2nd generation protein pharmaceuticals. The company was sold to Maxygen, Inc. one year after inception for stock worth about USD 75 mill.
From 1992 to 1999, Dr. Hansen held executive positions at Novo Nordisk A/S, including as Director of Intellectual Property Strategy, which is one of his core areas of expertise. In this capacity, Dr. Hansen was responsible for numerous patent, license and collaborative agreement strategies and negotiations, and was a member of Research Management.
Dr. Hansen holds an MSc (1989) in chemical engineering, a PhD (1992) in molecular biology/biochemistry and an MBA.
Dr. Hansen is listed as inventor in connection with more than 15 patent applications.
|
| |
|
| |
|
 |
Stephen J. Petti
Stephen Petti is a Blue Note co-Founder and serves as the Company's President and CEO. A veteran of more than 20 years in the drug development business, Mr. Petti was the co-Founder of Empire Pharmaceuticals, which was acquired in 2004 by Neurobiologic Technologies of Emeryville, California (NASDAQ:NTII). He was also instrumental in building and advancing DOV Pharmaceutical from start-up to IPO in the space of three years.
Mr. Petti's complete bio can be accessed on the "Management" page.
|
| |
|
| |
|
|
|
